Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
2020 · Cell · 487 citations
https://doi.org/10.1016/j.cell.2020.04.020
Y
Yanxia Liu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
49
Papers
5.5K
Citations
27
h-index
29
i10-index
Yanxia Liu is an academic researcher from Weifang Medical University. The author has contributed to research in topics: CRISPR and Genetic Engineering & Pluripotent Stem Cells Research & Genetics, Aging, and Longevity in Model Organisms. The author has an h-index of 27, co-authored 42 publications.
ORCID: 0000-0002-6550-3624Papers by this author
worksYAP Induces Human Naive Pluripotency
2016 · Cell Reports · 212 citations
https://doi.org/10.1016/j.celrep.2016.02.036
Microvesicles derived from hypoxia/reoxygenation-treated human umbilical vein endothelial cells promote apoptosis and oxidative stress in H9c2 cardiomyocytes
2016 · BMC Cell Biology · 59 citations
https://doi.org/10.1186/s12860-016-0100-1
CRISPhieRmix: a hierarchical mixture model for CRISPR pooled screens
2018 · Genome biology · 53 citations
https://doi.org/10.1186/s13059-018-1538-6
Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro
2022 · Nature Communications · 46 citations
https://doi.org/10.1038/s41467-022-30546-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat